Ihsane Hmamouchi, ACR 2020 – Clomipramine for Chronic Lumbar Radicular Pain
We were delighted to speak to Ihsane Hmamouchi regarding the use of clomipramine for the treatment of chronic lumbar radicular pain. The abstract ‘Efficacy of Clomipramine for Chronic Lumbar Radicular Pain a Randomized Clinical Trial’ (ABSTRACT NUMBER: 0962) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- What is the rationale for the use of clomipramine for chronic lumbar radicular pain? (0:27)
- What were the aims and design of the recent clinical trial you are presenting? (1:40)
- What were the efficacy and safety findings of this study? (4:25)
- What are the implications of these findings for future clinical practice? (6:10)
- What factors should clinicians consider when prescribing clomipramine in this treatment setting? (6:51)
Disclosures: Ihsane Hmamouchi has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Rheumatic Diseases
Machine-learning models as predictors of fractures in osteoporosis: Giovanni Adami, WCO-IOF-ESCEO 2023
In this study a machine-learning approach was investigated over two years to determine the efficacy of fracture risk prediction in osteoporosis. touchIMMUNOLOGY were delighted to speak with Dr. Giovanni Adami (University of Verona, Verona, Italy) to discuss the machine-learning models already available for screening osteoporosis and their limitations, the risk factors used as predictors of […]
Patrick Durez, ACR 2022: Factors associated with disease flare following COVID vaccination in inflammatory rheumatic and musculoskeletal diseases
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
Robert Spiera, ACR 2022: Sarilumab for glucocorticoid resistant polymyalgia rheumatica – the SAPHYR study
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!